Post by Allucent

On Monday, Bruce McClenathan, Executive Medical Director at Allucent, joined the HHS, FDA, and other agencies for a roundtable on the future of clinical trials in the U.S. The discussion highlighted several topics that could have meaningful impact on drug development, including efforts to create a pilot program to shorten the path from drug discovery to first-in-human Phase 1 trials, as well as initiatives to streamline study activation and improve enrollment in cancer clinical trials. These efforts have the potential to help bring new therapies to patients faster while reducing some of the operational hurdles that sponsors face today. At Allucent, our Government & Regulatory Affairs team is tracking these developments closely and sharing industry perspectives with the FDA, while helping clients navigate what these changes may mean for their programs. #Allucent #BringingNewTherapiesToLight #RegulatoryAffairs #ClinicalTrials #ClinicalResearch #FDA #HHS #DrugDevelopment #Oncology #Biotech #Pharma